Cadrenal Therapeutics, Inc. Logo

Cadrenal Therapeutics, Inc.

Developing novel anticoagulant therapies for high-risk cardiovascular patients.

CVKD | NDAQ

Overview

Corporate Details

ISIN(s):
US1276361086
LEI:
Country:
United States of America
Address:
822 A1A NORTH, 32082 PONTE VEDRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel anticoagulant therapies to address critical gaps in cardiovascular care. The company's mission is to create safer and more effective treatments with greater predictability and control, thereby reducing the risks of both clotting and bleeding. Its clinical-stage pipeline includes two primary assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings. Cadrenal targets underserved, high-risk patient populations, including those with end-stage kidney disease and atrial fibrillation, as well as patients with implanted cardiac devices, aiming to reshape the standards of care in anticoagulation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cadrenal Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cadrenal Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cadrenal Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea 471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea 068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America CVM
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America CNTA
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America CERO

Talk to a Data Expert

Have a question? We'll get back to you promptly.